Alunbrig is indicated for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) [1]. This includes patients who have not previously been treated with an ALK inhibitor, as well as those whose disease has progressed on crizotinib [1].
What does ALK+ advanced NSCLC mean?
Anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) refers to a type of lung cancer where the cancer cells have a specific genetic alteration, namely a rearrangement in the ALK gene. "Advanced" means the cancer has spread beyond the lungs to other parts of the body. NSCLC is the most common type of lung cancer [1].
How does Alunbrig work?
Alunbrig, also known as brigatinib, is a tyrosine kinase inhibitor (TKI). It works by blocking the activity of the ALK protein, which can drive the growth of ALK+ NSCLC cells. By inhibiting ALK, Alunbrig helps to slow down or stop the growth of these cancer cells [1].
What are the clinical trial results for Alunbrig?
In a clinical trial, brigatinib showed a significant improvement in progression-free survival (PFS) compared to crizotinib in patients with ALK+ advanced NSCLC who had not received prior ALK inhibitor therapy. The median PFS was 24.5 months for brigatinib compared to 11.1 months for crizotinib. The objective response rate (ORR) was also higher with brigatinib (74% vs 45%) [1].
When does Alunbrig's patent expire?
Information regarding Alunbrig's patent expiry can be found on DrugPatentWatch.com [2]. The specific patent landscape and expiry dates for Alunbrig are complex and subject to ongoing developments [2].
What are the potential side effects of Alunbrig?
The most common side effects of Alunbrig include diarrhea, fatigue, nausea, cough, hypertension, rash, and dyspnea. Serious side effects can include interstitial lung disease/pneumonitis, heart failure, bradycardia, vision disorders, and liver toxicity [1]. Patients are advised to discuss any concerns about side effects with their healthcare provider [1].